Biofrontera Inc (BFRI) Stock Price, Quote & News

Company Profile

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 781 245 1325

Website: www.biofrontera-us.com

Address:

660 Main Street, 1st Floor, Woburn, United States

GlennSantos153 Jun. 29 at 7:24 AM

$BFRI what' your price target

0 · Reply

Tonyboner Jun. 26 at 1:38 PM

$BFRI Biotech in the biggest rally for 6 years and this is heading down,

0 · Reply

Tonyboner Jun. 25 at 8:06 PM

$BFRI Well this one turned out to be a POS, ca not hold any gains and then met with selling when it does, I suspect the company are diluting some how.

0 · Reply

jshlam Jun. 22 at 3:34 PM

$BFRI starter here

0 · Reply

gkluck Jun. 16 at 8:15 PM

$BFRI - this will be interesting to watch in next couple of days.. have a FDA approval in pipeline

0 · Reply

BananaBrawler Jun. 15 at 7:35 PM

$BFRI

0 · Reply

Kings124566 Jun. 15 at 7:26 PM

$BFRI The thing I disagree with you on is that trading volume on any given day means anything as far as the far as where the stock price is headed.

0 · Reply

Kings124566 Jun. 15 at 6:38 PM

$BFRI My bad. I reread your entire message and I see you brought facts to back up your point.

0 · Reply

Kings124566 Jun. 14 at 2:47 AM

$BFRI Sounds like voodoo

1 · Reply

BioSpecialOne Jun. 12 at 2:31 PM

$BFRI ‏BFRI is getting interesting here. Small float, low valuation, regulatory catalyst ahead, and volume is starting to matter. This is the kind of setup I like to watch closely when biotech sentiment improves. No guarantees, but the risk reward is worth .paying attention to

0 · Reply

Biofrontera Transcript: AGM 2026

May 28, 2026, 11:00 AM EDT - 4 weeks ago

Biofrontera Transcript: Lytham Partners Spring 2026 Investor Conference

May 21, 2026, 9:15 AM EDT - 5 weeks ago

Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

BFRIW

2026-05-19T10:15:31.000Z - 5 weeks ago

Biofrontera downgraded to Speculative Buy from Buy at Benchmark

May 14, 2026, 11:00 AM EDT - 6 weeks ago

Biofrontera Earnings Call Transcript: Q1 2026

May 14, 2026, 11:00 AM EDT - 6 weeks ago

Biofrontera Earnings release: Q1 2026

May 14, 2026, 11:00 AM EDT - 6 weeks ago

Biofrontera Quarterly report: Q1 2026

May 13, 2026, 9:00 AM EDT - 6 weeks ago

Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Biofrontera Proxy statement: Proxy filing

Mar 19, 2026, 10:00 AM EDT - 3 months ago

Biofrontera Earnings Call Transcript: Q4 2025

Mar 19, 2026, 10:00 AM EDT - 3 months ago

Biofrontera Annual report: Q4 2025

Mar 19, 2026, 10:00 AM EDT - 3 months ago

Biofrontera Earnings release: Q4 2025

2026-03-19T13:36:56.000Z - 3 months ago

Biofrontera reports Q4 revenue $17.1M vs. $12.6M last year

Mar 19, 2026, 9:25 AM EDT - 3 months ago

Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Mar 9, 2026, 5:25 PM EDT - 3 months ago

Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

2026-03-09T13:27:24.000Z - 3 months ago

Biofrontera reports Phase 2b results of Ameluz PDT in acne vulgaris

Mar 9, 2026, 9:15 AM EDT - 3 months ago

Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

2026-02-26T14:20:40.000Z - 4 months ago

Biofrontera reports USPTO decision on Sun Pharma’s challenged claims

Feb 26, 2026, 9:15 AM EST - 4 months ago

U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be Unpatentable

2026-02-17T14:27:27.000Z - 4 months ago

Biofrontera announces database lock of Phase 1 PK study of Ameluz

Feb 17, 2026, 9:15 AM EST - 4 months ago

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities

2026-02-11T14:20:35.000Z - 4 months ago

Biofrontera announces FDA acceptance of sNDA for Ameluz PDT

Feb 11, 2026, 9:15 AM EST - 4 months ago

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma

2026-02-09T14:25:30.000Z - 4 months ago

Biofrontera announces positive Phase 3 results for Ameluz PDT

Feb 9, 2026, 9:15 AM EST - 4 months ago

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint

Jan 15, 2026, 8:30 AM EST - 5 months ago

Biofrontera Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

2026-01-13T13:36:29.000Z - 5 months ago

Biofrontera reports preliminary Q4 revenue $17M-$17.5M

Jan 13, 2026, 8:30 AM EST - 5 months ago

Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth

2026-01-08T14:01:20.000Z - 6 months ago

Biofrontera announces data base locks for two clinical studies

Jan 8, 2026, 8:45 AM EST - 6 months ago

Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones

2025-12-18T13:51:20.000Z - 6 months ago

Biofrontera completes transfer of Ameluz, RhodoLED FDA approval

Dec 18, 2025, 8:45 AM EST - 6 months ago

Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio

2025-12-05T22:20:26.000Z - 7 months ago

Biofrontera Inc. files to sell 4M shares of common stock for holders

Dec 5, 2025, 7:00 AM EST - 7 months ago

Biofrontera Registration statement: Registration Filing

2025-12-04T14:15:22.000Z - 7 months ago

Biofrontera completes final patient visit in Phase 1 PK study of Ameluz gel

Dec 4, 2025, 9:00 AM EST - 7 months ago

Last Patient Completes Biofrontera's Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities

2025-12-02T13:50:16.000Z - 7 months ago

Biofrontera files sNDA for Ameluz-PDT in treatment of sBCC

Dec 2, 2025, 8:45 AM EST - 7 months ago

Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT

Nov 13, 2025, 10:00 AM EST - 8 months ago

Biofrontera Earnings Call Transcript: Q3 2025

Nov 13, 2025, 10:00 AM EST - 8 months ago

Biofrontera Earnings release: Q3 2025

Nov 13, 2025, 10:00 AM EST - 8 months ago

Biofrontera Quarterly report: Q3 2025

2025-11-13T13:21:24.000Z - 8 months ago

Biofrontera reports Q3 EPS (62c) vs (98c) last year

Nov 13, 2025, 8:15 AM EST - 8 months ago

Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update

2025-11-07T15:25:21.000Z - 8 months ago

Roth views divestiture as ‘essentially found money’ for Biofrontera

2025-11-07T13:10:26.000Z - 8 months ago

Pelthos Therapeutics acquires Xepi Cream from Biofrontera, Ferrer

LGND PTHS

2025-11-07T13:05:20.000Z - 8 months ago

Biofrontera announces sale of license for Xepi Cream to Pelthos

PTHS

Nov 7, 2025, 8:00 AM EST - 8 months ago

Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M

Nov 6, 2025, 4:01 PM EST - 8 months ago

Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025

2025-10-23T12:55:43.000Z - 8 months ago

Biofrontera Inc. close purchase of all Ameluz, RhodoLED U.S. assets

Oct 23, 2025, 8:45 AM EDT - 8 months ago

Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG

2025-10-02T21:15:07.000Z - 9 months ago

Biofrontera Inc. price target lowered to $9 from $10 at Roth Capital

Sep 30, 2025, 1:15 PM EDT - 9 months ago

Biofrontera Transcript: Lytham Partners Fall 2025 Investor Conference

Sep 26, 2025, 9:15 AM EDT - 9 months ago

Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Sep 23, 2025, 9:20 AM EDT - 9 months ago

Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program

Sep 16, 2025, 10:30 AM EDT - 10 months ago

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk

Aug 25, 2025, 8:25 AM EDT - 10 months ago

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Aug 14, 2025, 10:00 AM EDT - 11 months ago

Biofrontera Earnings Call Transcript: Q2 2025

Aug 14, 2025, 10:00 AM EDT - 11 months ago

Biofrontera Earnings release: Q2 2025

Aug 14, 2025, 10:00 AM EDT - 11 months ago

Biofrontera Quarterly report: Q2 2025

Aug 13, 2025, 5:20 PM EDT - 11 months ago

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

Aug 13, 2025, 8:00 AM EDT - 11 months ago

Biofrontera Registration statement: Registration Filing

Aug 11, 2025, 4:25 PM EDT - 11 months ago

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Biofrontera Proxy statement: Proxy Filing

Aug 4, 2025, 2:00 PM EDT - 11 months ago

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

Jul 25, 2025, 8:00 AM EDT - 1 year ago

Biofrontera Proxy statement: Proxy Filing

Jul 16, 2025, 8:00 AM EDT - 1 year ago

Biofrontera Registration statement: Registration Filing

Jun 30, 2025, 8:00 AM EDT - 1 year ago

Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment

Jun 11, 2025, 3:00 PM EDT - 1 year ago

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

Jun 3, 2025, 2:30 PM EDT - 1 year ago

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Biofrontera Proxy statement: Proxy Filing

May 16, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Earnings Call Transcript: Q1 2025

May 16, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Earnings release: Q1 2025

May 16, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Quarterly report: Q1 2025

May 15, 2025, 5:09 PM EDT - 1 year ago

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

May 15, 2025, 12:17 PM EDT - 1 year ago

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

May 6, 2025, 12:45 PM EDT - 1 year ago

Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025

May 1, 2025, 2:38 PM EDT - 1 year ago

Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Biofrontera Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Biofrontera Proxy statement: Proxy Filing

Mar 21, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Earnings Call Transcript: Q4 2024

Mar 21, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Earnings release: Q4 2024

Mar 21, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Annual report: Q4 2024

Mar 21, 2025, 8:00 AM EDT - 1 year ago

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

Mar 18, 2025, 9:30 AM EDT - 1 year ago

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

Mar 11, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

Jan 17, 2025, 7:00 AM EST - 1 year ago

Biofrontera Registration statement: Registration Filing

Jan 8, 2025, 9:50 AM EST - 1 year ago

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Dec 23, 2024, 9:30 AM EST - 1 year ago

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Dec 3, 2024, 11:00 AM EST - 1 year ago

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Nov 22, 2024, 9:10 AM EST - 1 year ago

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Nov 14, 2024, 10:00 AM EST - 1 year ago

Biofrontera Earnings Call Transcript: Q3 2024

Nov 14, 2024, 10:00 AM EST - 1 year ago

Biofrontera Quarterly report: Q3 2024

Nov 14, 2024, 10:00 AM EST - 1 year ago

Biofrontera Earnings release: Q3 2024

Nov 13, 2024, 5:15 PM EST - 1 year ago

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

Nov 1, 2024, 11:55 AM EDT - 1 year ago

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

Oct 31, 2024, 10:32 AM EDT - 1 year ago

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Oct 14, 2024, 10:30 AM EDT - 1 year ago

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Oct 7, 2024, 8:45 AM EDT - 1 year ago

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Sep 25, 2024, 10:45 AM EDT - 1 year ago

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference

Aug 15, 2024, 10:00 AM EDT - 2 years ago

Biofrontera Earnings Call Transcript: Q2 2024

Aug 15, 2024, 10:00 AM EDT - 2 years ago

Biofrontera Quarterly report: Q2 2024

Aug 15, 2024, 10:00 AM EDT - 2 years ago

Biofrontera Earnings release: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 2 years ago

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 9, 2024, 10:00 AM EDT - 2 years ago

Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024

Jun 24, 2024, 8:30 AM EDT - 2 years ago

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

May 16, 2024, 10:00 AM EDT - 2 years ago

Biofrontera Earnings Call Transcript: Q1 2024

May 16, 2024, 10:00 AM EDT - 2 years ago

Biofrontera Quarterly report: Q1 2024

May 16, 2024, 10:00 AM EDT - 2 years ago

Biofrontera Earnings release: Q1 2024

May 15, 2024, 4:45 PM EDT - 2 years ago

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update

May 6, 2024, 10:30 AM EDT - 2 years ago

Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024

GlennSantos153 Jun. 29 at 7:24 AM

$BFRI what' your price target

0 · Reply

Tonyboner Jun. 26 at 1:38 PM

$BFRI Biotech in the biggest rally for 6 years and this is heading down,

0 · Reply

Tonyboner Jun. 25 at 8:06 PM

$BFRI Well this one turned out to be a POS, ca not hold any gains and then met with selling when it does, I suspect the company are diluting some how.

0 · Reply

jshlam Jun. 22 at 3:34 PM

$BFRI starter here

0 · Reply

gkluck Jun. 16 at 8:15 PM

$BFRI - this will be interesting to watch in next couple of days.. have a FDA approval in pipeline

0 · Reply

BananaBrawler Jun. 15 at 7:35 PM

$BFRI

0 · Reply

Kings124566 Jun. 15 at 7:26 PM

$BFRI The thing I disagree with you on is that trading volume on any given day means anything as far as the far as where the stock price is headed.

0 · Reply

Kings124566 Jun. 15 at 6:38 PM

$BFRI My bad. I reread your entire message and I see you brought facts to back up your point.

0 · Reply

Kings124566 Jun. 14 at 2:47 AM

$BFRI Sounds like voodoo

1 · Reply

BioSpecialOne Jun. 12 at 2:31 PM

0 · Reply

Kings124566 Jun. 5 at 10:00 PM

$BFRI Jfin and Lx are already profitable, pay a dividend, and well below book value and super low P/E ratios.

0 · Reply

Tonyboner Jun. 5 at 7:06 PM

$BFRI Total market crash

0 · Reply

FreeRunner Jun. 5 at 6:05 PM

$BFRI Legitimate question : How a company with $10M revenue for Q1 can be valued at $12M? What am I missing?

1 · Reply

ivo98 Jun. 5 at 2:11 PM

$BFRI FDA Decision on 28 September is not for a new product, it's for use Ameluz. Bfri sales only 1 product and lamps. Be aware of pumping new members with there "28 September". 12 mlj outstanding and increasing. 🤔🤫

0 · Reply

race2zero Jun. 4 at 12:53 PM

$BFRI $CLDI $DOGZ $GRRR deep value for $CLDI? Yes, please join us in shorting it . Reverse split vote ends next Thursday (perfect for a Friday PR). 1-16 split with 9+ million dilution built in. Will be the easiest short ever

0 · Reply

tiddyy Jun. 3 at 3:19 PM

$BBAI Took some change out but I am back again after making some money on $BFRI

1 · Reply

ivo98 Jun. 3 at 2:01 PM

$BFRI @Tonyboner if you have Q1 10.08 mlj revenues and 14.4 mlj total operating expenses we are talking about a cash-burning company. They did not touch their cash but used other assets. These are not finite, and they will quickly use up their cash and need new ones (offering). They have only 1 drug approved and selling --> Ameluz. Most trials are with Ameluz and for a different working area and with/or a RhodoLED lamp.

1 · Reply

ivo98 Jun. 3 at 6:33 AM

$BFRI >12 mlj outstanding shares and not enough cash to survive 2026 without making a new offering. 1 product "Ameluz" sales.

1 · Reply

Tonyboner Jun. 2 at 6:01 PM

$BFRI Looks like int are buying slowly, good moves in the last few weeks, think this blows soon, like to see $1.50S on this one. they have cash and very low float, with a few million shares we will see some big moves, they have a lot of drugs approved.

0 · Reply

LongBullish Jun. 2 at 4:44 PM

$BFRI Transformed its business by acquiring full U.S. commercial rights for its flagship photodynamic therapy drug, Ameluz. The FDA set a critical PDUFA action date of September 28, 2026, to review Ameluz for superficial basal cell carcinoma. What's taking $NWBO so long with DCVax-L?

1 · Reply

Tonyboner Jun. 2 at 4:04 PM

$BFRI $1.20 is big break to upside, 3rd time lucky watch.

0 · Reply

Tonyboner Jun. 2 at 4:01 PM

$BFRI Im supprised there are only a few watchers playing this one, going up on 2 of the worst biotech days is a good sign not a bad one.

0 · Reply

Market Cap	12.43M
Revenue (ttm)	41.71M
Net Income (ttm)	-10.54M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-25.27%
Debt to Equity Ratio	0.78

Volume	250,700
Avg Vol	225,290
Day's Range	N/A - N/A
Shares Out	12.80M
Stochastic %K	37%
Beta	0.83
Analysts	Sell
Price Target	$6.00